Agios Q3: PYRUKYND rev $7.4M; first patient dosed in Phase 3 sickle cell; net loss $91.3M

AGIOS PHARMACEUTICALS, INC.

2023-Q3 EPS reported -$4.61 revenue$19,720,000

PYRUKYND net revenue $7.4M in Q3 2023 (+10% QoQ); 100 patients on therapy, 160 completed enrollment forms.
First patient dosed in Phase 3 portion of RISE UP pivotal study of mitapivat in sickle cell disease.
Completed enrollment in Phase 3 ACTIVATE-kidsT; >50% enrolled in Phase 3 ACTIVATE-kids for pediatric PK deficiency.
Net loss $91.3M in Q3 2023 vs $81.7M in Q3 2022; cash $872.4M as of Sep 30, 2023, funding into 2026.
Topline data for AG-946 in LR-MDS expected by year-end 2023; Phase 3 thalassemia data in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $7.4 million, net income $91.3 million net loss.

Period: third quarter ended September 30, 2023
Revenue: $7.4 million
Net income: $91.3 million net loss
Result: reported results

Exact text from the filing

Data Readouts in Two Phase 3 Trials of Mitapivat in Thalassemia Next Year and Topline Data for AG-946 in LR-MDS by Year-end 2023 – – U.S. PYRUKYND ® (mitapivat) Net Revenue of $7.4 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $872.4 Million as of September 30, 2023 – CAMBRIDGE, Mass., November 2, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq:

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-23-000138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.